Unicycive is a biotechnology company developing drug candidates for kidney disease, including treatments for dialysis patients. UNCY reports earnings on Wed, Nov 11, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).
Prices, price targets and earnings estimates for UNCY are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
No whale options trades in UNCY in the last 90 days.
Total alerts
0
Bullish
0
0%
Bearish
0
0%
Date span
—
Loading…
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether UNCY is in one of them and how their past UNCY trades turned out.
Unicycive is a biotechnology company based in Mountain View, California, that is developing drugs for kidney disease. Its lead candidate, oxylanthanum carbonate, is a tablet meant to control high phosphorus levels in patients on dialysis, and it is designed to be swallowed whole rather than chewed. Its second candidate, UNI-494, is in development for acute kidney injury, a condition for which no FDA approved medicines currently exist. The company plans to seek approvals in the United States and to partner with other drugmakers in other markets.
